PDF(Pubmed)
Abstract：
M2 tumor-associated macrophage (M2 TAM), a crucial component of the tumor microenvironment, has a significant impact on tumor invasion and metastasis in the form of angiogenesis for lung adenocarcinoma (LUAD). In this study, both single-cell RNA and bulk RNA sequencing data were analyzed to identify 12 M2 TAM and angiogenesis-related genes (OLR1, CTSL, HLA-DPB1, NUPR1, ALOX5, DOCK4, CSF2RB, PTPN6, TNFSF12, HNRNPA2B1, NCL, and BIRC2). These genes were used to construct a prognostic signature, which was subsequently validated using an external cohort. Moreover, the immune profile analysis indicated that the low-risk group exhibited a distinct immune cell infiltration and relatively active status. Importantly, the prognostic signature was closely associated with PD-1, CTLA4, tumor mutation burden, and anti-cancer drug sensitivity. In summary, this study proposes a new prognostic signature for patients with LUAD based on M2 TAM and angiogenesis-related genes. The signature forecasts the prognosis of LUAD by an independent manner, reveals the potential molecular mechanisms involved in tumor immune-related functions, and offers appropriate clinical strategies for the treatment of patients with LUAD.
摘要：
M2肿瘤相关巨噬细胞（M2TAM），肿瘤微环境的重要组成部分，肺腺癌(LUAD)血管生成对肿瘤侵袭和转移有显著影响。在这项研究中,分析单细胞RNA和批量RNA测序数据，以鉴定12个M2TAM和血管生成相关基因(OLR1，CTSL，HLA-DPB1,NUPR1,ALOX5,DOCK4,CSF2RB,PTPN6,TNFSF12,HNRNPA2B1,NCL,和BIRC2）。这些基因被用来构建预后标签，随后使用外部队列进行了验证。此外，免疫谱分析表明,低危组表现出明显的免疫细胞浸润和相对活跃的状态.重要的是,预后特征与PD-1，CTLA4，肿瘤突变负荷，和抗癌药物敏感性。总之,这项研究提出了基于M2TAM和血管生成相关基因的LUAD患者的新预后特征.签名通过独立的方式预测LUAD的预后，揭示了参与肿瘤免疫相关功能的潜在分子机制，并为LUAD患者的治疗提供适当的临床策略。
